12:55 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

Pyrimidinol-based inhibitor of MAP4K4 for myocardial infarction

DISEASE CATEGORY: Cardiovascular INDICATION: Myocardial infarction (MI) Patient sample, in vitro , cell culture and mouse studies identified a pyrimidinol-based inhibitor of MAP4K4 that could help treat MI. In patients with chronic heart failure, levels...
07:00 , Apr 2, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4; MEKKK4)

Cancer INDICATION: Cancer; Ophthalmic Mouse studies suggest MAP4K4 inhibition could help treat cancer and ophthalmic indications. In normal mice, knockout of MAP4K4 in endothelial cells decreased cell proliferation and vascular development compared with normal MAP4K4...
07:00 , May 21, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

This week in techniques Approach Summary Licensing status Publication and contact information Drug delivery Orally delivered small interfering RNA A b1,3-d-glucan-encapsulated oral delivery vehicle could be a useful tool for delivering siRNA to macrophages and...
07:00 , May 21, 2009 |  BC Innovations  |  Tools & Techniques

Orally delivered siRNA

A group at the University of Massachusetts Medical School has developed an encapsulated formulation of small interfering RNA that allows for oral delivery of the therapeutics and directs the siRNAs to their target cells. 1...